KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Gerd Burmester, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec, Sławomir Jeka, Rafał Wojciechowski, Katarzyna Kolossa, Anna Dudek, Magdalena Krajewska-Włodarczyk, Paweł Hrycaj, Piotr Adrian Klimiuk, SungHyun Kim, JeeHye Suh, GoEun Yang, YunAh Kim, YooBin Jung, GaHee Park, Josef S Smolen

Clin Drug Investig 45(8) 551-563

PMID40650731
PMCIDPMC12307557
DOI10.1007/s40261-025-01453-8
发表日期2025-07-12
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:ROC 图;Fig. 3:ROC 图。
摘要

摘要

BACKGROUND AND OBJECTIVE: This phase III study conducted in 22 centres in Poland assessed the efficacy equivalence of candidate tocilizumab biosimilar, CT-P47, and European Union-approved reference tocilizumab (r-TCZ) in rheumatoid arthritis. We report 1-year data, including switching from r-TCZ to CT-P47. METHODS: This active-controlled, double-blind, multicentre trial randomised (1:1) adults (aged 18-75 years) with moderate-to-severe rheumatoid arthritis diagnosed for ≥ 24 weeks and treated with methotrextate for ≥ 12 weeks before the first study drug administration, to receive CT-P47 or r-TCZ every 4 weeks (8 mg/kg, intravenous) up to week 20. At week 24, those on CT-P47 continued maintenance treatment; those on r-TCZ were re-randomised (1:1) to continue r-TCZ (r-TCZ maintenance) or to switch to CT-P47 (CT-P47 switched) until week 48 (Treatment Period 2). After week 48, patients were followed up until week 52 (end of study). Efficacy, pharmacokinetics, safety and immunogenicity were evaluated. RESULTS: In Treatment Period 2, 225 patients continued CT-P47 maintenance, 109 continued r‑TCZ maintenance and 110 switched to CT-P47. During Treatment Period 2, efficacy findings were comparable between groups. At week 52, the mean change from baseline in Disease Activity Score in 28 joints-erythrocyte sedimentation rate was - 4.279, - 4.231 and - 4.376 in the CT-P47 maintenance, r-TCZ maintenance and CT-P47 switched groups, respectively. Joint damage progression over 1 year was minimal in all groups. Drug serum concentrations were relatively consistent throughout Treatment Period 2. The safety profile and antidrug antibody-positive conversion rate (< 5% in each group) were similar between groups. CONCLUSIONS: Week 52 results show maintained efficacy after switching from r-TCZ to CT-P47, and comparable efficacy, pharmacokinetics, safety and immunogenicity of CT-P47 versus r-TCZ over 1 year of treatment. CLINICAL TRIAL REGISTRATION: NCT05489224, 24 July 2022.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition (intent-to-treat set and intent-to-treat in Treatment Period 2 subset). a Prior to dosing at week 24, all patients underwent a second randomisation process. Patients who were initially randomised to reference tocilizumab (r-TCZ) were randomised (1:1) to either continue with r-TCZ (r-TCZ maintenance) or switch to CT-P47 (CT-P47 switched) every 4 weeks until week 48. Patients who were initially randomised to CT-P47 were to continue treatment with CT-P47 every 4 weeks until week 48. After week 48, all patients were followed up until week 52 (end of study). b One patient in the CT-P47 maintenance group is not included as the patient completed the study drug and then terminated the study. TP1 Treatment Period 1, TP2 Treatment Period 2
非 KM Figure
Fig. 2Fig. 2 Efficacy results in Treatment Period 2 (intent-to-treat Treatment Period 2 set). Mean change from baseline in Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) [ a ]. Mean change from baseline in DAS28-C-reactive protein (CRP) [ b ]. Mean change from baseline in Simplified Disease Activity Index (SDAI) [ c ]. Mean change from baseline in Clinical Disease Activity Index (CDAI) [ d ]. 20% improvement according to American College of Rheumatology (ACR) criteria (ACR20), 50% improvement according to ACR criteria (ACR50) and 70% improvement according to ACR criteria (ACR70) response rates at weeks 24, 36 and 52 (end of study) [ e ]. Data are prior to administration of the study drug at each timepoint. Therefore, patients in the CT-P47 switched group had not yet received CT-P47 when week 24 measurements were taken. r-TCZ reference tocilizumab, SD standard deviation
非 KM Figure
Fig. 3Fig. 3 Post hoc analysis of Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) < 2.6 and low disease activity (LDA) [ a ], American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) index-based remission and LDA by Simplified Disease Activity Index (SDAI) [ b ] and Clinical Disease Activity Index (CDAI) [ c ] and ACR/EULAR Boolean-based remission ( d ) in Treatment Period 2 (intent-to-treat Treatment Period 2 subset). Data are prior to administration of the study drug at each timepoint. Therefore, patients in the CT-P47 switched group had not yet received CT-P47 when week 24 measurements were taken. a DAS28-ESR score categorised x < 2.6 and LDA (2.6 ≤ x ≤ 3.2). b SDAI score categorised as remission ( x ≤ 3.3) and LDA (3.3 < x ≤ 11.0). c CDAI score categorised as remission ( x ≤ 2.8) and LDA (2.8 < x ≤ 10.0). d ACR/EULAR remission using the Boolean-based 2.0 definition must satisfy all of the following: tender joint count ≤ 1 (of 28 assessed); swollen joint count ≤ 1 (of 28 assessed); C-reactive protein ≤ 1 mg/dL; patient’s global assessment of disease activity (visual analogue scale) ≤ 2 (when converted to 0–10 cm). r-TCZ reference tocilizumab
非 KM Figure